Cargando…

Systemic counterregulatory response of angiopoietin‐2 after aflibercept therapy for nAMD: a potential escape mechanism

PURPOSE: To analyse the effect of intravitreal aflibercept injections on systemic angiopoietin‐2 (Ang2) and vascular endothelial growth factor (VEGF)‐A levels in patients with neovascular age‐related macular degeneration (nAMD). METHODS: In a prospective, randomized study, aflibercept (2.0 mg/50 µl)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angermann, Reinhard, Rauchegger, Teresa, Nowosielski, Yvonne, Seifarth, Christof, Egger, Stefan, Kralinger, Martina T., Kieselbach, Gerhard F., Zehetner, Claus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519089/ https://www.ncbi.nlm.nih.gov/pubmed/33326179 http://dx.doi.org/10.1111/aos.14691

Ejemplares similares

Effects of Intravitreal Aflibercept on the Systemic Insulin-like Growth Factor-I and Vascular Endothelial Growth Factor-A in Patients with Diabetic Retinopathy and Age-Related Macular Degeneration
por: Huber, Anna Lena, et al.
Publicado: (2021)

CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
por: Angermann, Reinhard, et al.
Publicado: (2022)

Aflibercept Does Not Suppress Angiopoietin-2 in Patients With nAMD or DME
por: Avery, Robert L., et al.
Publicado: (2023)

The impact of compliance among patients with diabetic macular oedema treated with intravitreal aflibercept: a 48‐month follow‐up study
por: Angermann, Reinhard, et al.
Publicado: (2021)

Efficiency benchmarks in the surgical management of primary rhegmatogenous retinal detachment: a monocentric register cohort study of operating room time metrics and influential factors
por: Angermann, Reinhard, et al.
Publicado: (2021)

Effect of Timing on Visual Outcomes in Fovea-Involving Retinal Detachments Verified by SD-OCT
por: Angermann, Reinhard, et al.
Publicado: (2020)

Long-term persistence with aflibercept therapy among treatment-naïve patients with exudative age-related macular degeneration in a universal health care system: a retrospective study
por: Angermann, Reinhard, et al.
Publicado: (2022)

Impact of submacular fluid volume on visual outcome in macula‐off rhegmatogenous retinal detachment using automated optical coherence tomography volumetric quantification
por: Angermann, Reinhard, et al.
Publicado: (2021)

Bilateral cataract surgery improves neurologic brake reaction time and stopping distance in elderly drivers
por: Nowosielski, Yvonne, et al.
Publicado: (2021)

Intravitreal Aflibercept Therapy and Treatment Outcomes of Eyes with Neovascular Age-Related Macular Degeneration in a Real-Life Setting: A Five-Year Follow-Up Investigation
por: Angermann, Reinhard, et al.
Publicado: (2022)

Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD
por: Kiss, Szilárd, et al.
Publicado: (2020)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
por: Ferrante, Nicola, et al.
Publicado: (2022)

Proton beam radiation for iris melanoma: case series and review of literature
por: Hauzinger, Jasmine Alexandra, et al.
Publicado: (2021)

Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab
por: Tran, Thi Ha Chau, et al.
Publicado: (2017)

Communicating with patients with nAMD and their families during the COVID-19 pandemic
por: Korobelnik, Jean-François, et al.
Publicado: (2020)

Corrigendum to “Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab”
por: Tran, Thi Ha Chau, et al.
Publicado: (2018)

Effects of COVID-19 protective measures on the ophthalmological patient examination with an emphasis on gender-specific differences
por: Rauchegger, Teresa, et al.
Publicado: (2021)

New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)
por: Patel, Prem, et al.
Publicado: (2021)

A model to quantify the influence of treatment patterns and optimize outcomes in nAMD
por: Ziemssen, Focke, et al.
Publicado: (2022)

Strongest Correlation Between Contrast Sensitivity and Morphological Characteristics in Bilateral nAMD
por: Hoffmann, Laura, et al.
Publicado: (2021)

Impact of intravitreal injection therapy on contrast sensitivity in patients with nAMD and DME
por: Dieke, Sebastian, et al.
Publicado: (2023)

Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial
por: Heier, Jeffrey S., et al.
Publicado: (2022)

A serum metabolomics study of patients with nAMD in response to anti-VEGF therapy
por: Gao, Yan, et al.
Publicado: (2020)

Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients
por: Skelly, Adrian, et al.
Publicado: (2019)

The Efficacy and Safety of Brolucizumab for the Treatment of nAMD: A Systematic Review and Meta-Analysis
por: Chuan, Junlan, et al.
Publicado: (2022)

Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
por: Sarkar, Aira, et al.
Publicado: (2021)

Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options
por: Tan, Colin S, et al.
Publicado: (2022)

nAMD: optimization of patient care and patient-oriented information with the help of an internet-based survey
por: Schmid, Anke, et al.
Publicado: (2022)

The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis
por: Danyliv, Andriy, et al.
Publicado: (2017)

Aflibercept in wet AMD: specific role and optimal use
por: Semeraro, F, et al.
Publicado: (2013)

Erratum to: The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis
por: Danyliv, Andriy, et al.
Publicado: (2017)

Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD
por: Chakravarthy, Usha, et al.
Publicado: (2021)

Through the Eyes of Patients: Understanding Treatment Burden of Intravitreal Anti-VEGF Injections for nAMD Patients in Norway
por: Reitan, Gudrun, et al.
Publicado: (2023)

Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER
por: Tadayoni, Ramin, et al.
Publicado: (2023)

Predictors of persistent disease activity following anti-VEGF loading dose for nAMD patients in Singapore: the DIALS study
por: Tan, Colin S., et al.
Publicado: (2020)

Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results
por: Neves Cardoso, Pedro, et al.
Publicado: (2017)

Lentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD
por: Iqball, Sharifah, et al.
Publicado: (2023)

Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service
por: Gale, Richard P., et al.
Publicado: (2019)

A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
por: Johnston, Robert L., et al.
Publicado: (2017)

Contrast sensitivity and binocular reading speed best correlating with near distance vision‐related quality of life in bilateral nAMD
por: Rossouw, Petra, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cm30u6v732eb38o976pgjus0cl